KRAS and pancreatic neoplasm: Since STAT3 phosphorylation/activation can be induced by MEK inhibitors, we hypothesize that the combined treatment with STAT3 and MEK inhibitors would have enhanced therapeutic effects in K-Ras mutant pancreatic cancer and colon cancer cells compared with MEK or STAT3 inhibitor alone.